Targeting metabolism and survival in chronic lymphocytic leukemia and richter syndrome cells by a novel NF-κB inhibitor

Haematologica

Volumn 102, Issue 11, 2017, Pages 1878-1889

  Vaisitti, Tiziana ^a,b   Gaudino, Federica ^a,b   Ouk, Samedy ^c   Moscvin, Maria ^b   Vitale, Nicoletta ^d   Serra, Sara ^a,b   Arruga, Francesca ^b   Zakrzewski, Johannes L ^e   Liou, Hsiou Chi ^c   Allan, John N ^f   Furman, Richard R ^f   Deaglio, Silvia ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b IIGM Italian Institute for Genomic Medicine   (Italy)

^c ImmuneTarget Inc   (United States)

^d UNIVERSITY OF TURIN   (Italy)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; CATALASE; CD86 ANTIGEN; CYTOCHROME C OXIDASE; IBRUTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; IT 901; PROGRAMMED DEATH 1 LIGAND 1; REACTIVE OXYGEN METABOLITE; ROTENONE; TRANSCRIPTION FACTOR REL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; CELL INTERACTION; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEPOLARIZATION; DNA BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; GENETIC STABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LYMPHOMA; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; RICHTER SYNDROME; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; WHOLE EXOME SEQUENCING; XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; ENERGY METABOLISM; GENETICS; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ENERGY METABOLISM; GENE SILENCING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NF-KAPPA B; PYRAZOLES; PYRIMIDINES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85032683905     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2017.173419     Document Type: Article

References (37)

1. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002; 3(3): 221-227.
2. Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ. 2006; 13(5): 759-772.
3. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009; 1(4): a000034.
4. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008; 132(3): 344-362.
5. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009; 27: 693-733.
6. Perkins ND. NF-kappaB: tumor promoter or suppressor? Trends Cell Biol. 2004; 14(2): 64-69.
7. Bradford JW, Baldwin AS. IKK/nuclear factor- kappaB and oncogenesis: roles in tumor-initiating cells and in the tumor microenvironment. Adv Cancer Res. 2014; 121: 125-145.
8. Gasparini C, Celeghini C, Monasta L, Zauli G. NF-kappaB pathways in hematological malignancies. Cell Mol Life Sci. 2014; 71(11): 2083-2102.
9. Cuni S, Perez-Aciego P, Perez-Chacon G, et al. A sustained activation of PI3K/NFkappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia. 2004; 18(8): 1391-1400.
10. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NFkappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol. 2000; 164(4): 2200-2206.
11. Lin Y, Bai L, Chen W, Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets. 2010; 14(1): 45-55.
12. Tracey L, Perez-Rosado A, Artiga MJ, et al. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small Bcell and aggressive B-cell lymphomas, respectively. J Pathol. 2005; 206(2): 123-134.
13. Hewamana S, Alghazal S, Lin TT, et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood. 2008; 111(9): 4681-4689.
14. Hewamana S, Lin TT, Rowntree C, et al. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J Clin Oncol. 2009; 27(5): 763-769.
15. Sutton LA, Rosenquist R. The complex interplay between cell-intrinsic and cellextrinsic factors driving the evolution of chronic lymphocytic leukemia. Semin Cancer Biol. 2015; 34: 22-35.
16. Bernal A, Pastore RD, Asgary Z, et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood. 2001; 98(10): 3050-3057.
17. Barragan M, Bellosillo B, Campas C, Colomer D, Pons G, Gil J. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood. 2002; 99(8): 2969-2976.
18. Zaninoni A, Imperiali FG, Pasquini C, Zanella A, Barcellini W. Cytokine modulation of nuclear factor-kappaB activity in Bchronic lymphocytic leukemia. Exp Hematol. 2003; 31(3): 185-190.
19. Petlickovski A, Laurenti L, Li X, et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood. 2005; 105(12): 4820-4827.
20. Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer. 2005; 103(2): 216-228.
21. Rossi D, Gaidano G. Richter syndrome: pathogenesis and management. Semin Oncol. 2016; 43(2): 311-319.
22. Fabbri G, Khiabanian H, Holmes AB, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med. 2013; 210(11): 2273-2288.
23. Shono Y, Tuckett AZ, Ouk S, et al. A smallmolecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity. Cancer Discov. 2014; 4(5): 578-591.
24. Shono Y, Tuckett AZ, Liou HC, et al. Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NFkappaB-Controlled Oxidative Stress Responses. Cancer Res. 2016; 76(2): 377-389.
25. Seiffert M, Stilgenbauer S, Dohner H, Lichter P. Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids. Leukemia. 2007; 21(9): 1977-1983.
26. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res. 2011; 21(1): 103-115.
27. Nakano H, Nakajima A, Sakon-Komazawa S, Piao JH, Xue X, Okumura K. Reactive oxygen species mediate crosstalk between NF-kappaB and JNK. Cell Death Differ. 2006; 13(5): 730-737.
28. Jitschin R, Hofmann AD, Bruns H, et al. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood. 2014; 123(17): 2663-2672.
29. Mauro C, Leow SC, Anso E, et al. NFkappaB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat Cell Biol. 2011; 13(10): 1272-1279.
30. Lutzny G, Kocher T, Schmidt-Supprian M, et al. Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell. 2013; 23(1): 77-92.
31. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell’Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000; 96(8): 2655-2663.
32. Jain P, Keating MJ, Wierda W, et al. Long term follow up of treatment with ibrutinib and rituximab (IR) in patients with highrisk Chronic Lymphocytic Leukemia (CLL). Clin Cancer Res. 2017; 23(9): 2154-2158.
33. Wiestner A. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma. Hematology Am Soc Hematol Educ Program. 2014; 2014(1): 125-134.
34. Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015; 3(3): e00149.
35. Vaisitti T, Audrito V, Serra S, et al. The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. Leukemia. 2015; 29(2): 356-368.
36. Bertilaccio MT, Scielzo C, Simonetti G, et al. Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. Leukemia. 2013; 27(3): 534-540.
37. Rossi D. Richter’s syndrome: Novel and promising therapeutic alternatives. Best Pract Res Clin Haematol. 2016; 29(1): 30-39.